Tempur-Pedic International Inc. (NYSE: TPX) shares increased 9.54% to $42 after the company’s net income fell to $23.5 million, or 39 cents per share, in the fourth quarter, from $56.3 million, or 84 cents per share, a year earlier. Adjusted earnings were 60 cents per share. Net sales fell 7% to $341.1 million. Analysts expected earnings of 55 cents per share, on revenue of $339 million.
Terex Corporation (NYSE: TEX) stock jumped 10.24% to $31.34. The company, on Jan. 15, reported in its Form 8-K that on January 14, 2013 that Kevin Bradley, currently President, Terex Cranes, will transition to the role of Senior Vice President and Chief Financial Officer (CFO) effective immediately after the filing of the Company's Annual Report on Form 10-K for 2012. Mr. Bradley, 50, was named President, Terex Cranes in January 2011. Prior to that, Mr. Bradley had served as President, Terex Financial Services since joining Terex in 2005.
QLogic Corporation (NASDAQ: QLGC) shares climbed 13.40% to $12.26 after the company reported third quarter income from continuing operations on a non-GAAP basis of $0.20 per share, as compared to $0.34 per share a year ago. The consensus estimate was for EPS of $0.18. Revenues were $119.4 million, compared to $142.8 million last year. The consensus estimate was for revenues of $117.45 million.
Additionally, Morgan Stanley upgraded shares of QLogic from an underweight rating to an equal weight rating in a research note released today.
Halliburton Company (NYSE: HAL) stock climbed 4.84% to $39.64 after the company reported a fourth quarter profit of $669 million, or 72 cents a share, down from $906 million, or 98 cents a share, a year earlier. Earnings from continuing operations were 63 cents, down from 98 cents. Revenue improved 3.2% to $7.29 billion. Analysts most recently projected earnings from continuing operations of 60 cents a share on revenue of $7.06 billion.
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) shares increased 8.45% to $5.32 after the company announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase 3 MAESTRO study assessing the efficacy and safety of investigational hypoxia-targeted drug TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Pacific Dynasty Consultants Inc.
2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062